Dr. Joseph Carroll, new Associate Director of the BDI



The BDI is delighted to announce the recent appointment of Dr. Joseph Carroll to the position of Associate Director of the Institute. Joseph brings his diverse background in commercializing technologies in the biotech arena to the BDI to oversee technology commercialization and alliance management.

Joseph received his B.S. in Biochemistry from Beloit College, his PhD from SUNY-Stony Brook in Cellular and Molecular Biology, and his post-doctoral training at Cancer Research UK (in the laboratory of Dr. Fiona Watt, FRS). Over the past 15 years he has worked at a number of pharmaceutical and biotech companies,  to utilize genomic technologies to improve drug development.

As a Principal Scientist at Wyeth (Cambridge, Mass), he worked on pre-clinical of inflammation and evaluated the efficacy therapeutic cytokines and their receptors in disease. He then move to Millennium Pharmaceuticals (Cambridge, Mass) as a Senior Scientist to head up the Hematology group and oversee the Hematology alliance with Bayer Pharmaceuticals to mine the human genome for novel drug targets in various hematologic disorders and initiate biomarker discovery. Out of Millennium, Joseph co-founded a start-up (Skinetics Biosciences, Inc., NY, NY) which focused on the therapeutic application of siRNAs in inflammatory skin disease. Skinetics Biosceinces was acquired by Sirna Therapeutics in 2004.

Joseph then moved to Sirna Therapeutics (Boulder, CO) as Director of Research, where he worked on therapeutic topical siRNAs until the acquisition of Sirna by Merck in 2007. Remaining in Boulder, Joseph moved to the Technology Transfer Office in 2007 where we was Licensing Manager, responsible for licensing technologies in the biotech and alternative energy arenas and was instrumental in helping to initiate several start-ups in these fields out of the University.